Systematic review of immunomodulatory therapies for hidradenitis suppurativa

Systematic review of immunomodulatory therapies for hidradenitis suppurativa

Shi Yu Derek Lim,1 Hazel H Oon21Internal Medicine Residency, National Healthcare Group, Singapore, Singapore; 2Department of Dermatology, National Skin Centre, Singapore, SingaporeBackground: Greater understanding of the roles of tumor necrosis factor-α, IL-1β, IL-10, and the IL-2...

Full description

Bibliographic Details
Main Authors:	Lim SYD, Oon HH
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-05-01
Series:	Biologics: Targets & Therapy
Subjects:	tumor necrosis factor adalimumab infliximab secukinumab guselkumab bermekimab
Online Access:	https://www.dovepress.com/systematic-review-of-immunomodulatory-therapies-for-hidradenitis-suppu-peer-reviewed-article-BTT

Similar Items

New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2023-05-01)

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
by: Fabrizio Martora, et al.
Published: (2023-04-01)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
by: Federica Repetto, et al.
Published: (2023-04-01)

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
by: Martora F, et al.
Published: (2024-02-01)

Management of severe hidradenitis suppurativa with biologic therapy and wide excision
by: Shi Yu Derek Lim, et al.
Published: (2019-05-01)

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa
by: Rene Chen, et al.
Published: (2024-02-01)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023-01-01)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
by: Ian Gorovoy, et al.
Published: (2009-10-01)

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
by: Alexander Egeberg, et al.
Published: (2024-03-01)

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
by: Martora F, et al.
Published: (2024-01-01)

Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review
by: Angelo Ruggiero, et al.
Published: (2022-02-01)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022-10-01)

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Golimumab Therapy in Ulcerative Colitis
by: Won Moon
Published: (2016-02-01)

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review
by: Marleen Bouhuys, et al.
Published: (2022-04-01)

A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact
by: Joana Roseira, et al.
Published: (2019-04-01)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
by: Silvia Marquez-Megias, et al.
Published: (2022-05-01)

Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease
by: Hannah S. Berman, et al.
Published: (2021-02-01)

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01)

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
by: Tai-Siang Chiu, et al.
Published: (2019-01-01)

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review
by: Javier Plaza, et al.
Published: (2024-03-01)

Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease
by: Karube H, et al.
Published: (2016-09-01)

ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
by: E. V. Voronina, et al.
Published: (2018-12-01)

Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study
by: Soo Min Ahn, et al.
Published: (2022-01-01)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
by: Cristiano Pagnini, et al.
Published: (2021-09-01)

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety
by: Astrid‐Helene Ravn Jørgensen, et al.
Published: (2020-12-01)

Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis
by: Teppei Hagino, et al.
Published: (2023-01-01)

Severe psoriatic arthritis in an HIV/AIDS patient treated with several TNF blockers switching: a case-based review
by: J. Carvalho, et al.
Published: (2022-01-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
by: Seung-Won Jung, et al.
Published: (2022-05-01)

The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate–Severe Crohn’s Disease: A Systematic Review
by: Ana Avedillo-Salas, et al.
Published: (2023-11-01)

Tratamiento biológico en psoriasis: Revisión bibliográfica Biologic therapy of psoriasis: Literature review
by: MS Lorenzetti, et al.
Published: (2012-06-01)

Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders
by: Dennis D. Arnold, et al.
Published: (2022-07-01)

Serum infliximab levels and clinical response in hidradenitis suppurativa
by: Erwin Benassaia, et al.
Published: (2023-06-01)

Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus
by: Farzan Solimani, et al.
Published: (2019-07-01)

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease
by: J Dretzke, et al.
Published: (2011-02-01)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
by: Fotiadou C, et al.
Published: (2016-10-01)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023-04-01)

Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report
by: Fan D, et al.
Published: (2024-03-01)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
by: Paolo Gisondi, et al.
Published: (2022-04-01)